awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38265472-3CAE1C22-47BE-4CAD-A63F-881ADFD203B1
Q38265472-3CAE1C22-47BE-4CAD-A63F-881ADFD203B1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38265472-3CAE1C22-47BE-4CAD-A63F-881ADFD203B1
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.
P2860
Q38265472-3CAE1C22-47BE-4CAD-A63F-881ADFD203B1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38265472-3CAE1C22-47BE-4CAD-A63F-881ADFD203B1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b5caf430a229e3c70ae6da2daef9025fc21d8693
P2860
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.